

# Dawood Darbar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4360634/publications.pdf>

Version: 2024-02-01

190  
papers

14,782  
citations

26630

56  
h-index

20961

115  
g-index

201  
all docs

201  
docs citations

201  
times ranked

17207  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. <i>Cell Genomics</i> , 2022, 2, 100084.	6.5	29
2	Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. <i>Nature Genetics</i> , 2022, 54, 263-273.	21.4	156
3	Mutant ANP induces mitochondrial and ion channel remodeling in a human iPSC-derived atrial fibrillation model. <i>JCI Insight</i> , 2022, 7, .	5.0	11
4	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. <i>Science Advances</i> , 2022, 8, eabl6579.	10.3	36
5	Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes. <i>JAMA Cardiology</i> , 2022, 7, 733.	6.1	14
6	The Value of Rare Genetic Variation in the Prediction of Common Obesity in European Ancestry Populations. <i>Frontiers in Endocrinology</i> , 2022, 13, 863893.	3.5	7
7	Unraveling the genomic basis of congenital heart disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	2
8	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. <i>Nature</i> , 2021, 590, 290-299.	27.8	1,069
9	Atrial Fibrillation in Inherited Channelopathies. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 155-163.	1.7	3
10	Atrial Fibrillation and Longitudinal Change in Cognitive Function in CKD. <i>Kidney International Reports</i> , 2021, 6, 669-674.	0.8	1
11	Bioengineering approaches to mature induced pluripotent stem cell-derived atrial cardiomyocytes to model atrial fibrillation. <i>Experimental Biology and Medicine</i> , 2021, 246, 1816-1828.	2.4	6
12	Genetics of atrial fibrillation—practical applications for clinical management: if not now, when and how?. <i>Cardiovascular Research</i> , 2021, 117, 1718-1731.	3.8	11
13	Common genetic variants associated with obesity in an African-American and Hispanic/Latino population. <i>PLoS ONE</i> , 2021, 16, e0250697.	2.5	13
14	Common genetic variation in circadian clock genes are associated with cardiovascular risk factors in an African American and Hispanic/Latino cohort. <i>IJC Heart and Vasculature</i> , 2021, 34, 100808.	1.1	5
15	Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation. <i>Stem Cell Reports</i> , 2021, 16, 1542-1554.	4.8	25
16	Association of Rare Genetic Variants and Early-Onset Atrial Fibrillation in Ethnic Minority Individuals. <i>JAMA Cardiology</i> , 2021, 6, 811.	6.1	30
17	Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. <i>JAMA Cardiology</i> , 2021, 6, 1371.	6.1	66
18	The Burden of Atrial Fibrillation in Sickle Cell Disease. <i>Blood</i> , 2021, 138, 3119-3119.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Clinical and Genetic Contributors to New-Onset Atrial Fibrillation in Critically Ill Adults*. Critical Care Medicine, 2020, 48, 22-30.	0.9	5
20	Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs. JAMA Cardiology, 2020, 5, 57.	6.1	22
21	Pathogenic mutations perturb calmodulin regulation of Nav1.8 channel. Biochemical and Biophysical Research Communications, 2020, 533, 168-174.	2.1	8
22	Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature, 2020, 586, 763-768.	27.8	376
23	Ion Channel and Structural Remodeling in Obesity-Mediated Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008296.	4.8	53
24	Deciphering the Electrophysiological Mechanisms for Ibrutinib-Induced Ventricular Arrhythmias. JACC: CardioOncology, 2020, 2, 630-631.	4.0	1
25	Impact of traditional risk factors for the outcomes of atrial fibrillation across race and ethnicity and sex groups. IJC Heart and Vasculature, 2020, 28, 100538.	1.1	5
26	Multi-Ethnic Genome-Wide Association Study of Decomposed Cardioelectric Phenotypes Illustrates Strategies to Identify and Characterize Evidence of Shared Genetic Effects for Complex Traits. Circulation Genomic and Precision Medicine, 2020, 13, e002680.	3.6	4
27	Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007676.	4.8	30
28	Genetic and Molecular Basis of Cardiac Arrhythmias. Contemporary Cardiology, 2020, , 75-96.	0.1	0
29	GWAS of QRS duration identifies new loci specific to Hispanic/Latino populations. PLoS ONE, 2019, 14, e0217796.	2.5	8
30	Whole Genome Sequencing Identifies CRISPLD2 as a Lung Function Gene in Children With Asthma. Chest, 2019, 156, 1068-1079.	0.8	5
31	Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2019, 132, 24-35.	1.9	19
32	Standard Antiarrhythmic Drugs. , 2018, , 1062-1075.		4
33	Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2018, 320, 2354.	7.4	144
34	Association Between Family History and Early-Onset Atrial Fibrillation Across Racial and Ethnic Groups. JAMA Network Open, 2018, 1, e182497.	5.9	23
35	Relation of Body Mass Index to Symptom Burden in Patients with Atrial Fibrillation. American Journal of Cardiology, 2018, 122, 235-241.	1.6	8
36	Is Achieving the American Heart Association's Life Simple 7 Goals Sufficient to Reduce the Burden of Atrial Fibrillation? No Simple Answers. Journal of the American Heart Association, 2018, 7, .	3.7	1

#	ARTICLE	IF	CITATIONS
37	Genetic modulation of atrial fibrillation risk in a Hispanic/Latino cohort. PLoS ONE, 2018, 13, e0194480.	2.5	12
38	Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Communications Biology, 2018, 1, 68.	4.4	42
39	Race and Socioeconomic Status Regulate Lifetime Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006584.	4.8	2
40	Electrophysiologic Characterization of Calcium Handling in Human Induced Pluripotent Stem Cell-Derived Atrial Cardiomyocytes. Stem Cell Reports, 2018, 10, 1867-1878.	4.8	48
41	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	21.4	552
42	Genetic Risk Scores for Atrial Fibrillation: Do They Improve Risk Estimation?. Canadian Journal of Cardiology, 2017, 33, 422-424.	1.7	10
43	Relation of Obstructive Sleep Apnea and a Common Variant at Chromosome 4q25 to Atrial Fibrillation. American Journal of Cardiology, 2017, 119, 1387-1391.	1.6	6
44	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nature Genetics, 2017, 49, 946-952.	21.4	279
45	Investigating the Genetic Architecture of the PR Interval Using Clinical Phenotypes. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	8
46	Genetic heterogeneity of atrial fibrillation susceptibility loci across racial or ethnic groups. European Heart Journal, 2017, 38, 2595-2598.	2.2	13
47	A Missense Variant in PLEC Increases Risk of Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 2157-2168.	2.8	73
48	Germline versus somatic mutations in genetic atrial fibrillation. Heart Rhythm, 2017, 14, 1539-1540.	0.7	0
49	The Pharmacogenomics of a Mutation "Hotspot" for the Short QT Syndrome. JACC: Clinical Electrophysiology, 2017, 3, 744-746.	3.2	1
50	Genetic Risk Prediction of Atrial Fibrillation. Circulation, 2017, 135, 1311-1320.	1.6	87
51	Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. PLoS ONE, 2017, 12, e0183690.	2.5	10
52	The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics. Journal of Cardiovascular Pharmacology, 2016, 67, 9-18.	1.9	16
53	A new paradigm for predicting risk of Torsades de Pointes during drug development: Commentary on: "Improved prediction of drug-induced Torsades de Pointes through simulations of dynamics and machine learning algorithms". Clinical Pharmacology and Therapeutics, 2016, 100, 324-326.	4.7	3
54	Measurement of diffuse ventricular fibrosis with myocardial T1 in patients with atrial fibrillation. Journal of Arrhythmia, 2016, 32, 51-56.	1.2	4

#	ARTICLE	IF	CITATIONS
55	Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. <i>JAMA Cardiology</i> , 2016, 1, 1007.	6.1	48
56	Variants in the <i>SCN5A</i> Promoter Associated With Various Arrhythmia Phenotypes. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	22
57	The “Double” Paradox of Atrial Fibrillation in Black Individuals. <i>JAMA Cardiology</i> , 2016, 1, 377.	6.1	15
58	Genotype influence in responses to therapy for atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1119-1131.	1.5	5
59	Gene-guided therapy for catheter-ablation of atrial fibrillation: are we there yet?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 45, 3-5.	1.3	2
60	Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients. <i>Cardiac Electrophysiology Clinics</i> , 2016, 8, 481-493.	1.7	12
61	Association of atrial fibrillation risk alleles and response to acute rate control therapy. <i>American Journal of Emergency Medicine</i> , 2016, 34, 735-740.	1.6	5
62	Atrial Fibrillation Is an Independent Predictor of Mortality in Critically Ill Patients*. <i>Critical Care Medicine</i> , 2015, 43, 2104-2111.	0.9	114
63	Ictal Asystole and Ictal Syncope. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 159-164.	4.8	68
64	Role of common and rare variants in <i>SCN10A</i> : results from the Brugada syndrome QRS locus gene discovery collaborative study. <i>Cardiovascular Research</i> , 2015, 106, 520-529.	3.8	108
65	Common Genetic Variants and Response to Atrial Fibrillation Ablation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 296-302.	4.8	98
66	The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2015, 104, 871-876.	3.3	147
67	Genetic and Clinical Risk Prediction Model for Postoperative Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 25-31.	4.8	49
68	Examining Rare and Low-Frequency Genetic Variants Previously Associated With Lone or Familial Forms of Atrial Fibrillation in an Electronic Medical Record System. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 58-63.	5.1	10
69	The AFFORD Clinical Decision Aid to Identify Emergency Department Patients With Atrial Fibrillation at Low Risk for 30-Day Adverse Events. <i>American Journal of Cardiology</i> , 2015, 115, 763-770.	1.6	24
70	Effect of Omega-Three Polyunsaturated Fatty Acids on Inflammation, Oxidative Stress, and Recurrence of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2015, 115, 196-201.	1.6	52
71	Severity of Obstructive Sleep Apnea Influences the Effect of Genotype on Response to Anti-Arrhythmic Drug Therapy for Atrial Fibrillation. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 503-507.	2.6	13
72	Suppression of Spontaneous Ca Elevations Prevents Atrial Fibrillation in Calsequestrin 2-Null Hearts. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 313-320.	4.8	52

#	ARTICLE	IF	CITATIONS
73	SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation. <i>Cardiovascular Research</i> , 2014, 104, 355-363.	3.8	65
74	Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. <i>Europace</i> , 2014, 16, 485-490.	1.7	24
75	Standard Antiarrhythmic Drugs. , 2014, , 1095-1110.		3
76	Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. <i>Global Cardiology Science &amp; Practice</i> , 2014, 2014, 5.	0.4	14
77	Prevalence and Predictors of Atrial Fibrillation Among Patients Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2014, 24, 611-616.	2.1	11
78	Whole-exome sequencing in familial atrial fibrillation. <i>European Heart Journal</i> , 2014, 35, 2477-2483.	2.2	42
79	Candidate gene approach to identifying rare genetic variants associated with lone atrial fibrillation. <i>Heart Rhythm</i> , 2014, 11, 46-52.	0.7	17
80	Atrial Fibrillation and SCN5A Variants. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 741-748.	1.7	13
81	Integrating Genetic, Transcriptional, and Functional Analyses to Identify 5 Novel Genes for Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 1225-1235.	1.6	183
82	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 772-791.	0.8	69
83	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, e153-e193.	0.8	236
84	A Common Variant on Chromosome 4q25 is Associated With Prolonged PR Interval in Subjects With and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 113, 309-313.	1.6	20
85	A Genome-Wide Association Study to Identify Genomic Modulators of Rate Control Therapy in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 114, 593-600.	1.6	15
86	Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene <i>GREM2</i> regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 332-41.	2.4	42
87	Relation of Morbid Obesity and Female Gender to Risk of Procedural Complications in Patients Undergoing Atrial Fibrillation Ablation. <i>American Journal of Cardiology</i> , 2013, 111, 368-373.	1.6	56
88	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Journal of the American College of Cardiology</i> , 2013, 61, e6-e75.	2.8	736
89	Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. <i>Heart Rhythm</i> , 2013, 10, 849-855.	0.7	82
90	Evaluating the HATCH score for predicting progression to sustained atrial fibrillation in ED patients with new atrial fibrillation. <i>American Journal of Emergency Medicine</i> , 2013, 31, 792-797.	1.6	17

#	ARTICLE	IF	CITATIONS
91	Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. <i>Nature Genetics</i> , 2013, 45, 621-631.	21.4	282
92	Genetic mechanisms of atrial fibrillation: impact on response to treatment. <i>Nature Reviews Cardiology</i> , 2013, 10, 317-329.	13.7	76
93	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Circulation</i> , 2013, 127, e283-352.	1.6	803
94	Selective Targeting of Gain-of-Function KCNQ1 Mutations Predisposing to Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 960-966.	4.8	40
95	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Circulation</i> , 2012, 126, 1784-1800.	1.6	321
96	A KCNJ8 mutation associated with early repolarization and atrial fibrillation. <i>Europace</i> , 2012, 14, 1428-1432.	1.7	103
97	A Common $\beta_1$ -Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 49-56.	2.8	84
98	2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, e127-e145.	0.8	44
99	Assessment of the Framingham risk factors among ED patients with newly diagnosed atrial fibrillation. <i>American Journal of Emergency Medicine</i> , 2012, 30, 151-157.	1.6	1
100	Relation of the Severity of Obstructive Sleep Apnea in Response to Anti-Arrhythmic Drugs in Patients With Atrial Fibrillation or Atrial Flutter. <i>American Journal of Cardiology</i> , 2012, 110, 369-372.	1.6	144
101	Repolarization Recipes for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1026-1028.	2.8	2
102	Symptomatic Response to Antiarrhythmic Drug Therapy Is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 539-545.	2.8	118
103	Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated With Familial Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1173-1181.	2.8	80
104	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1297-1313.	2.8	335
105	Risk Factors for Bradycardia Requiring Pacemaker Implantation in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2012, 110, 1315-1321.	1.6	23
106	Race-Specific Impact of Atrial Fibrillation Risk Factors in Blacks and Whites in the Southern Community Cohort Study. <i>American Journal of Cardiology</i> , 2012, 110, 1637-1642.	1.6	47
107	Meta-analysis identifies six new susceptibility loci for atrial fibrillation. <i>Nature Genetics</i> , 2012, 44, 670-675.	21.4	533
108	Characterization of Genome-Wide Association-Identified Variants for Atrial Fibrillation in African Americans. <i>PLoS ONE</i> , 2012, 7, e32338.	2.5	37

#	ARTICLE	IF	CITATIONS
109	Voltage-Gated Sodium Channels: Biophysics, Pharmacology, and Related Channelopathies. <i>Frontiers in Pharmacology</i> , 2012, 3, 124.	3.5	95
110	Novel ECG markers for ventricular repolarization: Is the QT interval obsolete?. <i>Heart Rhythm</i> , 2011, 8, 1044-1045.	0.7	1
111	Differential impact of race and risk factors on incidence of atrial fibrillation. <i>American Heart Journal</i> , 2011, 162, 31-37.	2.7	52
112	Genome-Wide Assessment for Genetic Variants Associated with Ventricular Dysfunction after Primary Coronary Artery Bypass Graft Surgery. <i>PLoS ONE</i> , 2011, 6, e24593.	2.5	5
113	A rare variant in MYH6 is associated with high risk of sick sinus syndrome. <i>Nature Genetics</i> , 2011, 43, 316-320.	21.4	275
114	The "missing" link in atrial fibrillation heritability. <i>Journal of Electrocardiology</i> , 2011, 44, 641-644.	0.9	19
115	Atrial fibrillation and flutter outcomes and risk determination (AFFORD): Design and rationale. <i>Journal of Cardiology</i> , 2011, 58, 124-130.	1.9	9
116	A Clinical Prediction Model to Estimate Risk for 30-Day Adverse Events in Emergency Department Patients With Symptomatic Atrial Fibrillation. <i>Annals of Emergency Medicine</i> , 2011, 57, 1-12.	0.6	56
117	Genetic and Molecular Basis of Arrhythmias. , 2011, , 65-86.		1
118	Drug-Induced Long QT Syndrome. <i>Pharmacological Reviews</i> , 2010, 62, 760-781.	16.0	374
119	Genomics, heart failure and sudden cardiac death. <i>Heart Failure Reviews</i> , 2010, 15, 229-238.	3.9	17
120	Common variants in KCNN3 are associated with lone atrial fibrillation. <i>Nature Genetics</i> , 2010, 42, 240-244.	21.4	438
121	Sodium Channel Variants Associated with Atrial Fibrillation Exhibit Abnormal Fast and Slow Inactivation. <i>Biophysical Journal</i> , 2010, 98, 310a.	0.5	1
122	Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. <i>Heart Rhythm</i> , 2010, 7, 1246-1252.	0.7	70
123	Triggers for cardiac events in patients with type 2 long QT syndrome. <i>Heart Rhythm</i> , 2010, 7, 1806-1807.	0.7	4
124	Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza. <i>Heart Rhythm</i> , 2010, 7, 1454-1457.	0.7	14
125	Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 181-190.	1.9	85
126	Role of inflammation and oxidative stress in atrial fibrillation. <i>Heart Rhythm</i> , 2010, 7, 438-444.	0.7	270



#	ARTICLE	IF	CITATIONS
127	Symptomatic Response to Antiarrhythmic Drug Therapy is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. <i>Heart Rhythm</i> , 2010, 7, 1721-1722.	0.7	0
128	Lone AF - Etiologic Factors and Genetic Insights into Pathophysiology. <i>Journal of Atrial Fibrillation</i> , 2010, 3, 236.	0.5	7
129	Atrial Fibrillation Susceptibility Alleles on Chromosome 4q25 Modulate Response to Catheter Ablation. <i>Journal of Atrial Fibrillation</i> , 2010, 3, 272.	0.5	1
130	Mutations in Sodium Channel $\beta$ 1- and $\beta$ 2-Subunits Associated With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 268-275.	4.8	212
131	A Genotype-Dependent Intermediate ECG Phenotype in Patients With Persistent Lone Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 24-28.	4.8	15
132	Prevention of Atrial Fibrillation. <i>Circulation</i> , 2009, 119, 606-618.	1.6	446
133	Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 499-506.	5.1	104
134	A sequence variant in ZFX3 on 16q22 associates with atrial fibrillation and ischemic stroke. <i>Nature Genetics</i> , 2009, 41, 876-878.	21.4	434
135	Is it time to develop a "pathogenicity" score to distinguish long QT syndrome causing mutations from "background" genetic noise?. <i>Heart Rhythm</i> , 2009, 6, 1304-1305.	0.7	8
136	ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: Implications for electrical remodeling. <i>Heart Rhythm</i> , 2009, 6, 1327-1332.	0.7	24
137	Arrhythmia Pharmacogenomics: Methodological Considerations. <i>Current Pharmaceutical Design</i> , 2009, 15, 3734-3741.	1.9	7
138	RHYTHM DISORDERS. , 2009, , 367-387.		0
139	Clinical use of and future perspectives on antiarrhythmic drugs. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1139-1146.	1.9	16
140	Persistent Atrial Fibrillation Is Associated With Reduced Risk of Torsades de Pointes in Patients With Drug-Induced Long QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2008, 51, 836-842.	2.8	43
141	Prolonged Signal-Averaged P-Wave Duration as an Intermediate Phenotype for Familial Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1083-1089.	2.8	59
142	Cardiac sodium channel variants: Action players with many faces. <i>Heart Rhythm</i> , 2008, 5, 1441-1443.	0.7	5
143	Genetics of atrial fibrillation: Rare mutations, common polymorphisms, and clinical relevance. <i>Heart Rhythm</i> , 2008, 5, 483-486.	0.7	30
144	Cardiac Sodium Channel ( <i>SCN5A</i> ) Variants Associated with Atrial Fibrillation. <i>Circulation</i> , 2008, 117, 1927-1935.	1.6	292

#	ARTICLE	IF	CITATIONS
145	Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. <i>European Heart Journal</i> , 2008, 30, 813-819.	2.2	193
146	Metabolic Syndrome and Risk of Development of Atrial Fibrillation. <i>Circulation</i> , 2008, 117, 1255-1260.	1.6	378
147	Atrial Natriuretic Peptide Frameshift Mutation in Familial Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2008, 359, 158-165.	27.0	300
148	Response to Letter Regarding Article, "Cardiac Sodium Channel ( SCN5A ) Variants Associated with Atrial Fibrillation". <i>Circulation</i> , 2008, 118, .	1.6	0
149	Abstract 4099: Genetic and Clinical Predictors of Response to Rate Control Therapy in Patients with Atrial Fibrillation. <i>Circulation</i> , 2008, 118, .	1.6	3
150	On the relationship among QT interval, atrial fibrillation, and torsade de pointes. <i>Europace</i> , 2007, 9, iv1-iv3.	1.7	13
151	A Shock in Time. <i>Clinical Journal of Sport Medicine</i> , 2007, 17, 497-499.	1.8	0
152	Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. <i>Heart Rhythm</i> , 2007, 4, 743-749.	0.7	92
153	A Rate-Independent Method of Assessing QT-RR Slope Following Conversion of Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 636-641.	1.7	24
154	Abstract 356: Loss of Function Mutations of Sodium Channel Beta-1 and Beta-2 Subunits Associated with Atrial Fibrillation and ST-segment Elevation. <i>Circulation</i> , 2007, 116, .	1.6	2
155	Screening for genomic alterations in congenital long QT syndrome. <i>Heart Rhythm</i> , 2006, 3, 56-57.	0.7	2
156	Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: Wide spectrum of disease in mutation carriers within a family. <i>Heart Rhythm</i> , 2006, 3, 939-944.	0.7	40
157	AB5-4. <i>Heart Rhythm</i> , 2006, 3, S10.	0.7	0
158	P1-84. <i>Heart Rhythm</i> , 2006, 3, S135-S136.	0.7	4
159	Pharmacogenetics of antiarrhythmic therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1583-1590.	1.8	24
160	Future of antiarrhythmic drugs. <i>Current Opinion in Cardiology</i> , 2006, 21, 361-367.	1.8	21
161	Recurrence of Atrial Tachyarrhythmias in Implantable Cardioverter-Defibrillator Recipients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005, 28, 1047-1051.	1.2	5
162	Himalayan T Waves in the Congenital Long-QT Syndrome. <i>Circulation</i> , 2005, 111, e161.	1.6	8

#	ARTICLE	IF	CITATIONS
163	Unmasking of Brugada Syndrome by Lithium. <i>Circulation</i> , 2005, 112, 1527-1531.	1.6	96
164	Congenital long QT syndrome aggravated by salt-wasting nephropathy. <i>Heart Rhythm</i> , 2005, 2, 304-306.	0.7	5
165	Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. <i>Heart Rhythm</i> , 2005, 2, 544-549.	0.7	29
166	Implantable Cardioverter-Defibrillator Malfunction due to Mechanical Failure of the Header Connection. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 1095-1099.	1.7	15
167	Effect of Peripheral Arterial Disease in Patients Undergoing Percutaneous Coronary Intervention With Intracoronary Stents. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1113-1118.	3.0	30
168	Effect of Peripheral Arterial Disease in Patients Undergoing Percutaneous Coronary Intervention With Intracoronary Stents. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1113-1118.	3.0	61
169	Familial atrial fibrillation is a genetically heterogeneous disorder. <i>Journal of the American College of Cardiology</i> , 2003, 41, 2185-2192.	2.8	309
170	Congenital right coronary artery aneurysm causing myocardial infarction, pseudoaneurysm formation, and right atrial compression. <i>Journal of the American Society of Echocardiography</i> , 2002, 15, 736-738.	2.8	2
171	P Wave Signal-Averaged Electrocardiography to Identify Risk for Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2002, 25, 1447-1453.	1.2	77
172	Sympathetic Activation Enhances QT Prolongation by Quinidine. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 9-14.	1.7	15
173	Localization of the Origin of Arrhythmias for Ablation: From Electrocardiography to Advanced Endocardial Mapping Systems. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 1309-1325.	1.7	19
174	Tremor-Induced ECG Artifact Mimicking Ventricular Tachycardia. <i>Circulation</i> , 2000, 102, 1337-1338.	1.6	42
175	Localized Aortic Dissection: Unusual Features by Transesophageal Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2000, 13, 1130-1134.	2.8	2
176	Exaggerated QT prolongation after cardioversion of atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 1999, 34, 396-401.	2.8	86
177	Modulation by Dietary Salt of Verapamil Disposition in Humans. <i>Circulation</i> , 1998, 98, 2702-2708.	1.6	31
178	Heart failure: a diagnostic and therapeutic dilemma in elderly patients. <i>Age and Ageing</i> , 1998, 27, 539-543.	1.6	4
179	Dietary salt increases first-pass elimination of oral quinidine*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 292-300.	4.7	40
180	Can qualitative echocardiography be used to select patients for angiotensin-converting enzyme inhibitors following acute myocardial infarction?. <i>European Heart Journal</i> , 1996, 17, 1783-1785.	2.2	6

#	ARTICLE	IF	CITATIONS
181	Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. American Journal of Health-System Pharmacy, 1996, 53, 655-658.	1.0	5
182	Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. American Journal of Cardiology, 1996, 77, 1351-1355.	1.6	46
183	Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial Infarction. American Journal of Cardiology, 1996, 78, 284-287.	1.6	123
184	Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. American Journal of Cardiology, 1996, 78, 736-740.	1.6	29
185	Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease. BMJ: British Medical Journal, 1996, 312, 874-878.	2.3	80
186	Algorithm to detect left ventricular dysfunction after myocardial infarction. BMJ: British Medical Journal, 1996, 312, 579-579.	2.3	0
187	ATTITUDES OF PHYSICIANS IN THE TREATMENT OF CONGESTIVE HEART FAILURE IN OLDER ADULTS. Journal of the American Geriatrics Society, 1995, 43, 943-944.	2.6	6
188	Predicting Ejection Fraction after Myocardial Infarction. Annals of Internal Medicine, 1995, 122, 729.	3.9	0
189	Genomics and Atrial Arrhythmias. , 0, , 65-79.		0
190	Genomics of the Drug-Induced Long-QT Syndrome. , 0, , 136-144.		0